BCM
RXII

Brookstone Capital Management’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Brookstone Capital Management’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-4,235
Closed -$7K – 1126
2015
Q3 		$7K Hold
4,235
– – ﹤0.01% 1313
2015
Q2 		$7K Buy
+4,235
New +$7K ﹤0.01% 1389

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Brookstone Capital Management's RXII Position: Q4 2015 in Review

Brookstone Capital Management sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2015, closing a stake of 4,235 shares — an estimated $7K sold.

Brookstone Capital Management first reported a position in RXII in Q2 2015 and held it in 2 quarters. The position peaked at $7K in Q3 2015. 83 funds tracked by Wall St. Rank hold RXII as of Q4 2015.

  • Brookstone Capital Management reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2015 after selling out during the quarter.
  • Brookstone Capital Management sold 4,235 GALENA BIOPHARMA INC COM shares in Q4 2015, an estimated $7K.
  • Brookstone Capital Management first reported a position in GALENA BIOPHARMA INC COM in Q2 2015 and held it in 2 quarters.
  • Brookstone Capital Management's GALENA BIOPHARMA INC COM position peaked at $7K in Q3 2015.
  • 83 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2015.

Based on Brookstone Capital Management's 13F filing for Q4 2015, filed 14 Jan 2016.